BEERSE, BELGIUM, May 05, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, announced today updated results from an open-label, multicentre, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non-muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.1 These data were featured today in an Oral Presentation Session (Abstract #PD48-02)1 at the 2024 American Urological Association (AUA) Annual Meeting taking place 3-6 May, 2024, in San Antonio, Texas.
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...
BEERSE, BELGIUM (22 April 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission (EC) has approved a Type II variation for CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel). This latest approval is for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI), have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.1
Janssen-Cilag`s Biologic Stelara (ustekinumab) Receives Approval in the U.S.
Johnson & Johnson submits application to the EMA for DARZALEX
Janssen`s Biologic Tecvayli (teclistamab) Receives Approval in the U.S.
Janssen`s Biologic Talvey (talquetamab-tgvs) Receives Approval in the U.S.
Janssen Submits Application to EMA Seeking Approval of RYBREVANT
Janssen-Cilag`s Talvey (talquetamab) Receives Approval in Europe
Janssen-Cilag International`s Tecvayli (teclistamab) Receives Approval in Europe